Mike Ralston, CEO of Blencowe Resources, explains the significance of the MSP for Orom-Cross. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Result of AGM

27 Jun 2024 16:02

RNS Number : 2206U
GENinCode PLC
27 June 2024
 

GENinCode Plc

("GENinCode" or the "Company")

 

Result of AGM

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

 

A copy of the voting results can be found on the website later today here.

 

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc

www.genincode.com or via Walbrook PR

Matthew Walls, CEO

Paul Foulger, CFO

 

Cavendish Capital Markets Limited

 

Tel: +44 (0)20 7397 8900

Giles Balleny / Dan Hodkinson (Corporate Finance)

Nigel Birks / Harriet Ward (Corporate Broking)

Dale Bellis / Michael Johnson (Sales)

 

Walbrook PR Limited

Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

Tel: 020 7933 8780 or genincode@walbrookpr.com  

 

 

About GENinCode:

 

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBSGDLRUDDGSR

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Track Your Investments

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.